[54] Use of the HLA-DR antigens incorporated into liposomes to generate HLA-DR specific cytotoxic T lymphocytes

Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens

“…Standard mAb IN-05 frequently used as a negative control (HofejSi et al 1984) was prepared in this laboratory. DR antigens were purified by immunoaffinity chromatography from crude membrane fraction of the homozygous LG-2 cell line (DR1, DQ1, DP probably 2, denoted as DP(2) throughout this paper) as described before (Gorga et al 1984). DQ and DP antigens were prepared in a similar way from this cell line, using immunosorbents prepared from appropriate monoclonal antibodies (Genox 3.53 and B7/21, respectively); details of their purification will be published elsewhere.…”

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

“…Nuinvolve interactions of antigen with macrophages as merous groups of investigators have used model memAPCs [73], and can also involve the participation of branes to mimic antigen-specific MHC 11-restricted CD4 + Th in the process of induction of CTLs [74]. In presentation to helper T cells [30,62,63,[76][77][78][79][80][81][82][83][84][85][86][87][88][89] and to a recent study the intracellular fate of a recombinant model or elicit specific CTLs in vitro [24,26,28,[90][91][92][93][94][95][96][97][98][99]. malarial antigen encapsulated in pH-insensitive lipoBiophysical aspects of T cell recognition of antigen on somes was investigated by the technique of immunosupported planar lipid membranes have been reviewed gold electron microscopy [47].…”

Specificity and Function of Immunogenic Peptides from the 35-Kilodalton Protein ofMycobacterium leprae

“…On the basis of the 35-kDa protein sequence (25), a total of 58 15-mer peptides overlapping by five residues were synthesized and characterized by previously described methods (23). HLA-DR molecules of 10 different haplotypes were purified (5,6), and the binding assay was performed with mixtures containing purified HLA-DR protein (0.5 M), N-terminally biotinylated reference peptide (1.8 M class II-associated invariant chain peptide [CLIP], 1.6 M influenza hemagglutinin 307-319, or 1.6 M HLA-A3 153-168), and competitor peptide (0, 3, 30, or 300 M) (11). The 50% inhibitory concentrations (IC 50 ) for competitor peptides were calculated by regression analysis of the measured absorbencies.…”